Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Cash And Cash Equivalents At Carrying Value of $89.74 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -14.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $14.02 million | Q3 2010: $11.17 million | Q1 2011: $31.34 million | Q2 2011: $17.01 million | Q3 2011: $22.44 million | Q1 2012: $27.66 million | Q2 2012: $21.92 million | Q3 2012: $23.96 million | Q1 2013: $14.81 million | Q2 2013: $19.77 million | Q3 2013: $26.05 million | Q1 2014: $13.58 million | Q2 2014: $121.52 million | Q3 2014: $121.16 million | Q1 2015: $48.37 million | Q2 2015: $76.78 million | Q3 2015: $46.63 million | Q1 2016: $12.90 million | Q2 2016: $8.66 million | Q3 2016: $35.39 million | Q1 2017: $75.16 million | Q2 2017: $39.70 million | Q3 2017: $117.78 million | Q1 2018: $43.77 million | Q2 2018: $27.10 million | Q3 2018: $52.58 million | Q1 2019: $34.80 million | Q2 2019: $30.76 million | Q3 2019: $29.90 million | Q1 2020: $101.87 million | Q2 2020: $173.47 million | Q3 2020: $96.49 million | Q1 2021: $226.90 million | Q2 2021: $210.31 million | Q3 2021: $199.60 million | Q1 2022: $395.50 million | Q2 2022: $272.57 million | Q3 2022: $246.90 million | Q1 2023: $155.14 million | Q2 2023: $146.22 million | Q3 2023: $150.91 million | Q1 2024: $84.33 million | Q2 2024: $78.41 million | Q3 2024: $96.84 million | Q1 2025: $105.19 million | Q2 2025: $88.03 million | Q3 2025: $84.08 million.
- Over the full 18 years of available data (2008 to 2025), BIOCRYST PHARMACEUTICALS INC's Cash And Cash Equivalents At Carrying Value has grown by 301.6%.
- Historical annual values: Fiscal year 2025: $89.74 million | Fiscal year 2024: $104.71 million | Fiscal year 2023: $110.64 million | Fiscal year 2022: $304.77 million | Fiscal year 2021: $504.39 million | Fiscal year 2020: $272.13 million | Fiscal year 2019: $114.17 million | Fiscal year 2018: $26.73 million | Fiscal year 2017: $50.28 million | Fiscal year 2016: $22.10 million | Fiscal year 2015: $28.90 million | Fiscal year 2014: $54.54 million | Fiscal year 2013: $21.16 million | Fiscal year 2012: $20.89 million | Fiscal year 2011: $16.44 million | Fiscal year 2010: $13.62 million | Fiscal year 2009: $41.13 million | Fiscal year 2008: $22.34 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: